Benign Prostatic Hyperplasia (BPH) Drugs Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Report ID: 52005 | Published Date: May 2025 | No. of Page: 111 | Base Year: 2024 | Rating: 4.4 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
Table of Contents
1  RESEARCH SCOPE
    1.1 Research Product Definition
    1.2 Research Segmentation
        1.2.1 Product Type
        1.2.2 Main product Type of Major Players
    1.3 Demand Overview
    1.4 Research Methodology
2 GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DRUGS INDUSTRY
    2.1 Summary about Benign Prostatic Hyperplasia (BPH) Drugs Industry
    2.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
        2.2.1 Benign Prostatic Hyperplasia (BPH) Drugs Production & Consumption Trends
        2.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Demand Structure Trends
    2.3 Benign Prostatic Hyperplasia (BPH) Drugs Cost & Price
3  MARKET DYNAMICS
    3.1 Manufacturing & Purchasing Behavior in 2020
    3.2 Market Development under the Impact of COVID-19
        3.2.1 Drivers
        3.2.2 Restraints
        3.2.3 Opportunity
        3.2.4 Risk
4  GLOBAL MARKET SEGMENTATION
    4.1 Region Segmentation (2017 to 2021f)
        4.1.1 North America (U.S., Canada and Mexico)
        4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
        4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
        4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
        4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)
    4.2 Product Type Segmentation (2017 to 2021f)
        4.2.1 Alpha-blocker
        4.2.2 Phosphodiesterase Type-5 Inhibitors
        4.2.3 5-alpha-Reductase Inhibitors
    4.3 Consumption Segmentation (2017 to 2021f)
        4.3.1 Hospitals
        4.3.2 Clinics
        4.3.3 Others
5  NORTH AMERICA MARKET SEGMENT
    5.1 Region Segmentation (2017 to 2021f)
        5.1.1 U.S.
        5.1.2 Canada
        5.1.3 Mexico
    5.2 Product Type Segmentation (2017 to 2021f)
        5.2.1 Alpha-blocker
        5.2.2 Phosphodiesterase Type-5 Inhibitors
        5.2.3 5-alpha-Reductase Inhibitors
    5.3 Consumption Segmentation (2017 to 2021f)
        5.3.1 Hospitals
        5.3.2 Clinics
        5.3.3 Others
    5.4 Impact of COVID-19 in North America
6  EUROPE MARKET SEGMENTATION
    6.1 Region Segmentation (2017 to 2021f)
        6.1.1 Germany
        6.1.2 UK
        6.1.3 France
        6.1.4 Italy
        6.1.5 Rest of Europe
    6.2 Product Type Segmentation (2017 to 2021f)
        6.2.1 Alpha-blocker
        6.2.2 Phosphodiesterase Type-5 Inhibitors
        6.2.3 5-alpha-Reductase Inhibitors
    6.3 Consumption Segmentation (2017 to 2021f)
        6.3.1 Hospitals
        6.3.2 Clinics
        6.3.3 Others
    6.4  Impact of COVID-19 in Europe
7  ASIA-PACIFIC MARKET SEGMENTATION
    7.1 Region Segmentation (2017 to 2021f)
        7.1.1 China
        7.1.2 India
        7.1.3 Japan
        7.1.4 South Korea
        7.1.5 Southeast Asia
        7.1.6 Australia
        7.1.7 Rest of Asia Pacific
    7.2 Product Type Segmentation (2017 to 2021f)
        7.2.1 Alpha-blocker
        7.2.2 Phosphodiesterase Type-5 Inhibitors
        7.2.3 5-alpha-Reductase Inhibitors
    7.3 Consumption Segmentation (2017 to 2021f)
        7.3.1 Hospitals
        7.3.2 Clinics
        7.3.3 Others
    7.4  Impact of COVID-19 in Europe
8  SOUTH AMERICA MARKET SEGMENTATION
    8.1 Region Segmentation (2017 to 2021f)
        8.1.1 Brazil
        8.1.2 Argentina
        8.1.3 Rest of Latin America
    8.2 Product Type Segmentation (2017 to 2021f)
        8.2.1 Alpha-blocker
        8.2.2 Phosphodiesterase Type-5 Inhibitors
        8.2.3 5-alpha-Reductase Inhibitors
    8.3 Consumption Segmentation (2017 to 2021f)
        8.3.1 Hospitals
        8.3.2 Clinics
        8.3.3 Others
    8.4  Impact of COVID-19 in Europe
9  MIDDLE EAST AND AFRICA MARKET SEGMENTATION
    9.1 Region Segmentation (2017 to 2021f)
        9.1.1 GCC
        9.1.2 North Africa
        9.1.3 South Africa
        9.1.4 Rest of Middle East and Africa
    9.2 Product Type Segmentation (2017 to 2021f)
        9.2.1 Alpha-blocker
        9.2.2 Phosphodiesterase Type-5 Inhibitors
        9.2.3 5-alpha-Reductase Inhibitors
    9.3 Consumption Segmentation (2017 to 2021f)
        9.3.1 Hospitals
        9.3.2 Clinics
        9.3.3 Others
    9.4  Impact of COVID-19 in Europe
10 COMPETITION OF MAJOR PLAYERS
    10.1 Brief Introduction of Major Players
        10.1.1 Astellas Pharma
        10.1.2 Eli Lilly
        10.1.3 GlaxoSmithKline
        10.1.4 Sanofi
        10.1.5 ADC Therapeutics
        10.1.6 Bayer HealthCare
        10.1.7 Bristol-Myers Squibb
        10.1.8 Valeant Pharmaceuticals
        10.1.9 Endo Pharmaceuticals
        10.1.10 Foresee Pharmaceuticals
        10.1.11 Madrigal Pharmaceuticals
        10.1.12 Merck
        10.1.13 Novartis
        10.1.14 Spectrum Pharmaceuticals
        10.1.15 Takeda Pharmaceuticals
        10.1.16 Teva
        10.1.17 Advaxis
        10.1.18 ANI Pharmaceuticals
        10.1.19 BHR Pharma
    10.2  Benign Prostatic Hyperplasia (BPH) Drugs Sales Date of Major Players (2017-2020e)
        10.2.1 Astellas Pharma
        10.2.2 Eli Lilly
        10.2.3 GlaxoSmithKline
        10.2.4 Sanofi
        10.2.5 ADC Therapeutics
        10.2.6 Bayer HealthCare
        10.2.7 Bristol-Myers Squibb
        10.2.8 Valeant Pharmaceuticals
        10.2.9 Endo Pharmaceuticals
        10.2.10 Foresee Pharmaceuticals
        10.2.11 Madrigal Pharmaceuticals
        10.2.12 Merck
        10.2.13 Novartis
        10.2.14 Spectrum Pharmaceuticals
        10.2.15 Takeda Pharmaceuticals
        10.2.16 Teva
        10.2.17 Advaxis
        10.2.18 ANI Pharmaceuticals
        10.2.19 BHR Pharma
    10.3  Market Distribution of Major Players
    10.4 Global Competition Segmentation
11  MARKET FORECAST
    11.1  Forecast by Region
    11.2  Forecast by Demand
    11.3  Environment Forecast
        11.3.1  Impact of COVID-19
        11.3.2  Geopolitics Overview
        11.3.3  Economic Overview of Major Countries
12  REPORT SUMMARY STATEMENT
List of Table
Table Benign Prostatic Hyperplasia (BPH) Drugs Product Type Overview
Table Benign Prostatic Hyperplasia (BPH) Drugs Product Type Market Share List
Table Benign Prostatic Hyperplasia (BPH) Drugs Product Type of Major Players
Table Brief Introduction of Astellas Pharma
Table Brief Introduction of Eli Lilly
Table Brief Introduction of GlaxoSmithKline
Table Brief Introduction of Sanofi
Table Brief Introduction of ADC Therapeutics
Table Brief Introduction of Bayer HealthCare
Table Brief Introduction of Bristol-Myers Squibb
Table Brief Introduction of Valeant Pharmaceuticals
Table Brief Introduction of Endo Pharmaceuticals
Table Brief Introduction of Foresee Pharmaceuticals
Table Brief Introduction of Madrigal Pharmaceuticals
Table Brief Introduction of Merck
Table Brief Introduction of Novartis
Table Brief Introduction of Spectrum Pharmaceuticals
Table Brief Introduction of Takeda Pharmaceuticals
Table Brief Introduction of Teva
Table Brief Introduction of Advaxis
Table Brief Introduction of ANI Pharmaceuticals
Table Brief Introduction of BHR Pharma
Table Products & Services of Astellas Pharma
Table Products & Services of Eli Lilly
Table Products & Services of GlaxoSmithKline
Table Products & Services of Sanofi
Table Products & Services of ADC Therapeutics
Table Products & Services of Bayer HealthCare
Table Products & Services of Bristol-Myers Squibb
Table Products & Services of Valeant Pharmaceuticals
Table Products & Services of Endo Pharmaceuticals
Table Products & Services of Foresee Pharmaceuticals
Table Products & Services of Madrigal Pharmaceuticals
Table Products & Services of Merck
Table Products & Services of Novartis
Table Products & Services of Spectrum Pharmaceuticals
Table Products & Services of Takeda Pharmaceuticals
Table Products & Services of Teva
Table Products & Services of Advaxis
Table Products & Services of ANI Pharmaceuticals
Table Products & Services of BHR Pharma
Table Market Distribution of Major Players
Table Global Major Players Sales Revenue (Million USD) 2017-2020e
Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (Million USD) by Region 2021f-2026f
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (Million USD) Share by Region 2021f-2026f
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (Million USD) by Demand 2021f-2026f
Table Global Benign Prostatic Hyperplasia (BPH) Drugs Market Forecast (Million USD) Share by Demand 2021f-2026f
List of Figure
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)
Figure Global Benign Prostatic Hyperplasia (BPH) Drugs Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)
Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Alpha-blocker Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Phosphodiesterase Type-5 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure 5-alpha-Reductase Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Alpha-blocker Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Phosphodiesterase Type-5 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure 5-alpha-Reductase Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Alpha-blocker Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Phosphodiesterase Type-5 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure 5-alpha-Reductase Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Alpha-blocker Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Phosphodiesterase Type-5 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure 5-alpha-Reductase Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Alpha-blocker Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Phosphodiesterase Type-5 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure 5-alpha-Reductase Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Alpha-blocker Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Phosphodiesterase Type-5 Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure 5-alpha-Reductase Inhibitors Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Hospitals Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Clinics Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Astellas Pharma 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Eli Lilly 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of GlaxoSmithKline 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Sanofi 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of ADC Therapeutics 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Bayer HealthCare 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Bristol-Myers Squibb 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Valeant Pharmaceuticals 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Endo Pharmaceuticals 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Foresee Pharmaceuticals 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Madrigal Pharmaceuticals 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Merck 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Novartis 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Spectrum Pharmaceuticals 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Takeda Pharmaceuticals 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Teva 2017-2020e
Figure Benign Prostatic Hyperplasia (BPH) Drugs Sales Revenue (Million USD) of Advaxis 2017-2020e
Figure  Sales Revenue (Million USD) of ANI Pharmaceuticals 2017-2020e
Figure  Sales Revenue (Million USD) of BHR Pharma 2017-2020e
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
Benign Prostatic Hyperplasia Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Benign Prostatic Hyperplasia Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Benign Prostatic Hyperplasia Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Berberine Market

Summary

Further key aspects of the report indicate that:
Chapter 1: Research Scope:  ... Read More

Beryllium Market

Summary

Further key aspects of the report indicate that:
Chapter 1: Research Scope:  ... Read More